Back grey_arrow_rt.gif
 
 
Gilead inks licensing pacts with 4 Indian firms
 
 
  2006-09-22 10:01
Moneycontrol.com
 
US drug maker Gilead has signed licensing agreements for its second-generation anti-AIDS drug Tenofovir with four Indian companies. CNBC-TV18 learns that it has chosen Aurobindo Pharma, JB Chemicals, Alkem and Shasun Chemicals for the deals.
 
Gilead also has similar deals with Strides Acrolab, Emcure and Hetero Drugs.
 
The US drug maker will provide manufacturing technology to these seven companies, and in return get a 5% royalty.
 
Gilead is also in talks with two companies for a marketing alliance to sell its branded anti-AIDS drug- Viread - in India.
 
Gregg H Alton, Sr VP, Gilead Sciences says, "We are in talks for this marketing alliance and we should be announcing something in the next 2 weeks."
 
Gilead has also filed a patent for Viread in India. But Cipla has opposed the pre-grant of the patent.
 
Matrix signs licensing agreement with US-based Gilead
 
Press Trust of India
Mumbai, September 22, 2006
 
Pharmaceutical company Matrix Laboratories Ltd on Friday said it signed a licensing agreement with Gilead for manufacture and sale of a generic version of Tenofovir Disoproxil Fumarate, an anti-AIDS therapy.
 
Tenofovir is a drug for second-line treatment of HIV/AIDS and was recently endorsed by WHO for first-line treatment as well, Matrix informed the Bombay Stock Exchange.
 
The company would have access to Gilead's technology for manufacture and sale of Tenofovir in 95 countries including India, it added.
 
In addition, the company would be able to make cost-saving modifications to the technology to enable improved access to the developing world. The company would also have the right to develop combination therapies using Tenofovir to enhance the effectiveness of existing therapies.
 
This license further boosts the company's significant portfolio of anti-retroviral APIs developed for combating HIV/AIDS.
 
Tenofovir is characterised by low incidence of resistance as compared to other first-line therapies.
 
Shares of the company were trading at Rs 269, down 0.20 per cent at the BSE.
 
 
 
 
  icon paper stack View Older Articles   Back to Top   www.natap.org